These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 25225706)

  • 1. Changes in regulations for approval of therapeutics.
    Reichert JM
    MAbs; 2010; 2(4):359-60. PubMed ID: 25225706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic monoclonal antibodies: trends in development and approval in the US.
    Reichert JM
    Curr Opin Mol Ther; 2002 Apr; 4(2):110-8. PubMed ID: 12044031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Similarity trials.
    Nat Biotechnol; 2011 Jan; 29(1):1. PubMed ID: 21221076
    [No Abstract]   [Full Text] [Related]  

  • 4. Monoclonal antibodies: production, uses and side effects.
    Cowden J; Parker SK
    Pediatr Infect Dis J; 2006 Jun; 25(6):553-5. PubMed ID: 16732156
    [No Abstract]   [Full Text] [Related]  

  • 5. Monoclonal antibody successes in the clinic.
    Reichert JM; Rosensweig CJ; Faden LB; Dewitz MC
    Nat Biotechnol; 2005 Sep; 23(9):1073-8. PubMed ID: 16151394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Difficult decisions.
    Nat Med; 2011 Aug; 17(8):901. PubMed ID: 21818065
    [No Abstract]   [Full Text] [Related]  

  • 7. Therapeutics: Spoilt for choice.
    Eisenstein M
    Nature; 2017 Nov; 551(7679):S36-S38. PubMed ID: 29117155
    [No Abstract]   [Full Text] [Related]  

  • 8. Anthrax drug first antibacterial mAb to win approval.
    Fox JL
    Nat Biotechnol; 2013 Jan; 31(1):8. PubMed ID: 23302914
    [No Abstract]   [Full Text] [Related]  

  • 9. [Regulatory consequences for the use of monoclonal antibodies].
    Lackner F; Behr-Gross ME
    Med Sci (Paris); 2009 Dec; 25(12):1183-8. PubMed ID: 20035703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Melanoma drug wins US approval.
    Ledford H
    Nature; 2011 Mar; 471(7340):561. PubMed ID: 21455150
    [No Abstract]   [Full Text] [Related]  

  • 11. Monoclonal antibody: the corner stone of modern biotherapeutics.
    Xia ZN; Cai XT; Cao P
    Yao Xue Xue Bao; 2012 Oct; 47(10):1275-80. PubMed ID: 23289138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reflections on historical, scientific, and legal issues relevant to designing approval pathways for generic versions of recombinant protein-based therapeutics and monoclonal antibodies.
    Dudzinski DM
    Food Drug Law J; 2005; 60(2):143-260. PubMed ID: 16094771
    [No Abstract]   [Full Text] [Related]  

  • 13. A Reality Check for Checkpoint Inhibitors.
    Reinke T
    Manag Care; 2018 May; 27(5):12-13. PubMed ID: 29763400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fearful of Avastin's fate, Genentech asks for unusual hearing.
    Ratner M
    Nat Med; 2011 Mar; 17(3):233. PubMed ID: 21383702
    [No Abstract]   [Full Text] [Related]  

  • 15. Setting the stage for biosimilar monoclonal antibodies.
    Schneider CK; Vleminckx C; Gravanis I; Ehmann F; Trouvin JH; Weise M; Thirstrup S
    Nat Biotechnol; 2012 Dec; 30(12):1179-85. PubMed ID: 23222783
    [No Abstract]   [Full Text] [Related]  

  • 16. Maintaining 'standards' for biosimilar monoclonal antibodies.
    Prior S; Metcalfe C; Hufton SE; Wadhwa M; Schneider CK; Burns C
    Nat Biotechnol; 2021 Mar; 39(3):276-280. PubMed ID: 33664522
    [No Abstract]   [Full Text] [Related]  

  • 17. Similarities and differences in the oncology drug approval process between FDA and European Union with emphasis on in vitro companion diagnostics.
    Senderowicz AM; Pfaff O
    Clin Cancer Res; 2014 Mar; 20(6):1445-52. PubMed ID: 24634467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Future of immunotherapy drug combinations and biomarkers.
    Schmidt C
    J Natl Cancer Inst; 2012 Mar; 104(6):434-9. PubMed ID: 22402694
    [No Abstract]   [Full Text] [Related]  

  • 19. Safe drugs and the cost of good intentions.
    Eichler HG; Abadie E; Raine JM; Salmonson T
    N Engl J Med; 2009 Apr; 360(14):1378-80. PubMed ID: 19339718
    [No Abstract]   [Full Text] [Related]  

  • 20. Informed by the European Union experience: what the United States can anticipate and learn from the European Union's regulatory approach to biosimilars.
    Gitter DM
    Seton Hall Law Rev; 2011; 41(2):559-92. PubMed ID: 21739759
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.